Cat's Claw — Benefits Deep Dive

Deep-Dive Articles

Back to Table of Contents

Table of Contents

1. Deep-Dive Articles
2. POA vs TOA — The Chemotype Selection Question
3. Why Cat's Claw Produces Effects (POA + Glycosides + Tannins)
4. What a Rheumatology Committee Reports
5. Cancer Fatigue and Quality of Life Studies
6. Key Research Papers
7. External Authoritative Resources
8. Connections
9. Featured Videos

POA vs TOA — The Chemotype Selection Question

The central claim about Cat's Claw products is that only those labeled POA-standardized or TOA-free deliver the published effects. The two chemotypes look identical, grow on the same vine species, and are sold under the same common name — but they are reported to act in opposite directions on the immune system, and in cell studies TOA reduced the activity of POA. A bottle labeled simply "Cat's Claw 500 mg" with no chemotype certification is described as a coin-flip on whether it carries any of the published clinical benefit at all.

The species Uncaria tomentosa contains two distinct populations of plants that produce different alkaloid profiles. Field botanists cannot tell them apart by appearance, leaf shape, or growing conditions — only laboratory chromatography can establish which chemotype a given bark harvest belongs to. The split was discovered and characterized by Austrian researcher Klaus Keplinger in the 1970s and 1980s, and the antagonism between the two alkaloid classes was demonstrated in subsequent work by Keplinger and Laus.

• Pentacyclic oxindole alkaloids (POA): isopteropodine, pteropodine, mitraphylline, speciophylline, isomitraphylline, uncarine F. These five-ring alkaloids are the immunomodulatory fraction. It is claimed that every positive Cat's Claw clinical trial used extracts standardized to POA content with TOA contamination below 0.5%. The published abstracts read differently: the Mur rheumatoid arthritis trial used an extract from the pentacyclic chemotype; the Piscoya osteoarthritis trial used freeze-dried Uncaria guianensis, a different species, and concluded that U. guianensis and U. tomentosa are “equiactive”; and the abstracts of the Sheng water-extract studies state no POA standard or TOA figure.
• Tetracyclic oxindole alkaloids (TOA): rhynchophylline and isorhynchophylline. These four-ring alkaloids have their own pharmacology — they are centrally acting, with effects on the central nervous system (CNS) and cardiovascular system — but in the context of Cat's Claw supplementation for immune support, they are described as unwanted. TOA actively antagonizes the immune-modulating effects of POA in cell work: Keplinger 1999 states that tetracyclic oxindole alkaloids “act as antagonists”, and Wurm 1998 reports that they dose-dependently reduce the activity of POA on human endothelial cells in culture. It is claimed that as little as 1% TOA content reduces POA immune activity by 30–70%, and that a bark harvest with 50% TOA may have no measurable immune effect at all, even at high doses; those percentages are not in either abstract.
• Why bulk “Cat's Claw” is called a coin flip: Roughly half of wild-harvested Uncaria tomentosa is said to be the TOA chemotype, a figure with no source on this page. The claim is that without laboratory testing and certification, a consumer purchasing generic bark powder or low-cost capsules is statistically likely to get a product with no clinical activity — or worse, a product with mixed chemotypes where the TOA actively cancels what little POA is present.
• Labels used in this market: “Pentacyclic oxindole alkaloid standardized”, “POA-standardized”, “TOA-free”, or specific certified extracts such as the preparation used in the Cowden Lyme protocol (certified TOA-free), the patented hot-water extract used in the Sheng DNA-repair study and other clinical research, and Keplinger's original European preparation. Those who hold this view regard generic capsules without chemotype certification as unreliable.
• Species substitution: The related species Uncaria guianensis is sometimes sold as Cat's Claw. It has its own pharmacology but a different alkaloid profile and far less research. The Piscoya 2001 osteoarthritis trial actually used U. guianensis, and there is reasonable evidence it is anti-inflammatory, but the immunomodulatory research base is almost entirely from U. tomentosa. The species, when stated, appears on the label.

Back to Table of Contents

Why Cat's Claw Produces Effects (POA + Glycosides + Tannins)

Most herbs have one or two principal active compounds. Cat's Claw has three distinct active fractions that work through three different mechanisms, and the clinical effect is the sum of all three. Understanding this is the difference between using the herb effectively and using it as a generic “immune supplement.”

1. Pentacyclic oxindole alkaloids — immune modulation. The POA fraction (isopteropodine, pteropodine, mitraphylline, uncarine F, speciophylline) is the immune-modulating fraction. Mechanism: enhanced phagocytosis in granulocytes and macrophages (40–60% in vitro at therapeutic concentrations), increased lymphocyte proliferation, enhanced natural killer-cell activity, and modulation of cytokine production. The research behind this is small. Wurm et al. (Planta Medica 1998) worked with endothelial cells in a dish: pentacyclic but not tetracyclic alkaloids made them release a factor that enhanced the growth of resting human lymphocytes. Sheng et al. (2001) gave a water extract to healthy adults in a 12-person study for 8 weeks and saw only a tendency toward increased lymphocyte growth. Piscoya et al. (2001) treated 45 people with knee osteoarthritis for 4 weeks, 30 on U. guianensis and 15 on placebo: pain on activity fell, while pain at rest or at night and knee circumference did not change significantly. This is the fraction that drives the immune-modulation deep-dive.
2. NF-kB inhibition — anti-inflammatory. This action is commonly credited to both alkaloids and triterpenes, and Cat's Claw is described as one of the most potent natural NF-kB inhibitors in botanical pharmacology. A 2002 study by Sandoval and colleagues reported a different picture for the alkaloids, in macrophage cells and an animal stomach-inflammation model: non-alkaloid fractions of U. tomentosa lowered tumor necrosis factor-alpha and nitrite at concentrations comparable to the whole plant, U. guianensis was more potent although U. tomentosa held 35-fold more oxindole and pentacyclic alkaloid, and the authors concluded that these alkaloids did not influence the anti-inflammatory and antioxidant properties. NF-kB is the master transcription factor controlling expression of tumor necrosis factor-alpha, interleukin-1 (IL-1), interleukin-6 (IL-6), cyclooxygenase-2 (COX-2), and dozens of other inflammatory mediators. By blocking NF-kB nuclear translocation, Cat's Claw reduces tumor necrosis factor-alpha output by >50% in macrophage models and is claimed to match the inflammatory end-point achieved by sulfasalazine in colitis models — without sulfasalazine's microbiome cost, sulfa allergy risk, or hematologic toxicity. The Sandoval-Chacon 1998 abstract reports no sulfasalazine comparison; it used cell lines and rats with indomethacin enteritis. This is the mechanism behind the anti-inflammatory deep-dive and the upstream driver of the rheumatoid arthritis trial results. Sandoval-Chacon and Sandoval mapped this pathway.
3. Quinovic acid glycosides + proanthocyanidin tannins — direct antimicrobial and DNA repair. The quinovic acid glycoside fraction has direct (modest) antibacterial and antiviral activity in vitro. The proanthocyanidin tannins disrupt bacterial cell membranes, chelate metals essential for pathogen metabolism, and have biofilm-disrupting activity that is one mechanistic rationale for the Lyme-disease adjunctive role. Separately, Sheng et al. reported that a water extract improved repair of DNA strand breaks in rats after irradiation and raised white cell counts in 4 healthy men (2000), and that in 12 healthy adults over 8 weeks it lowered DNA damage and raised DNA repair after a hydrogen peroxide challenge, compared with people not taking it (2001). This is described as involving base excision repair and nucleotide excision repair, pathways those abstracts do not name, and as a unique property not shared by most immune herbs, one that makes Cat's Claw structurally different from echinacea or astragalus.

The therapeutic implication: a high-quality POA-standardized whole-bark extract delivers all three fractions in their native ratio, which is the reason given for the claim that whole-plant preparations outperform isolated alkaloid concentrates; no published head-to-head comparison is named for it. The therapeutic complication: the same broad immune-activating profile described for chronic inflammation and infection susceptibility raises a concern for organ-transplant recipients on tacrolimus or cyclosporine, because an immune-activating herb may work against the medicines that hold back rejection, and for people with frank autoimmune disease, where the immune system is already overactive.

A 2024 laboratory study adds a concern about other medicines. Transporters are proteins that carry drugs into and out of cells. Cat's claw extract significantly blocked all the ATP-binding cassette (ABC) transporters tested and most of the solute carrier (SLC) transporters tested. From the concentration calculated for the gut, the authors judged that interactions with intestinal transporters could be relevant in the body, with possible results such as increased toxicity or altered effect of a medicine. This was work on cells and cell-derived vesicles, not a study in people.

Back to Table of Contents

What a Rheumatology Committee Reports

In 2026 a committee of the German Society for Rheumatology and Clinical Immunology published its review of 13 plant preparations often used in rheumatic disease, mostly as self-medication, including cat's claw. For all of them it found reports of anti-inflammatory or immune effects in the laboratory or in animals, but said the evidence for a clinically relevant benefit is “very limited” and that none of the preparations “can be recommended for use in inflammatory joint diseases”. That is the committee's position, reported here as such. Its separate list of plants that rheumatologists need not advise against when people take them for degenerative joint disease does not include cat's claw.

Back to Table of Contents

Cancer Fatigue and Quality of Life Studies

A Brazilian phase II study gave 100 mg of dry Uncaria tomentosa extract three times a day to 51 people with advanced solid tumors who had no further treatment options. Its abstract describes no comparison group. Overall quality of life (p = 0.0411) and social functioning (p = 0.0341) improved and fatigue fell (p = 0.0496). Inflammatory and blood markers did not change significantly, no tumor shrank by the study's criteria, the disease stayed stable for more than 8 months in four people, and most people tolerated the extract well. The authors wrote that the effect does not seem to come from the plant's anti-inflammatory properties.

A 2026 narrative review of cat's claw and two other plants for cancer fatigue, written by that study's senior author, points out a limit of this evidence: ten of the twelve clinical studies it covers come from his own institution. It calls the results preliminary and says larger placebo-controlled trials at several centers are still needed.

Back to Table of Contents

Key Research Papers

1. Mur E, Hartig F, Eibl G, Schirmer M (2002). Randomized double blind trial of an extract from the pentacyclic alkaloid-chemotype of Uncaria tomentosa for the treatment of rheumatoid arthritis. Journal of Rheumatology 29(4): 678–681. — PubMed PMID: 11950006
2. Sheng Y, Bryngelsson C, Pero RW (2000). Enhanced DNA repair, immune function and reduced toxicity of C-MED-100, a novel aqueous extract from Uncaria tomentosa. Journal of Ethnopharmacology 69(2): 115–126. — PubMed PMID: 10687868
3. Sandoval-Chacon M, Thompson JH, Zhang XJ, et al. (1998). Antiinflammatory actions of cat's claw: the role of NF-kappaB. Alimentary Pharmacology & Therapeutics 12(12): 1279–1289. — PubMed PMID: 9882039
4. Piscoya J, Rodriguez Z, Bustamante SA, et al. (2001). Efficacy and safety of freeze-dried cat's claw in osteoarthritis of the knee: mechanisms of action of the species Uncaria guianensis. Inflammation Research 50(9): 442–448. — PubMed PMID: 11603848
5. Keplinger K, Laus G, Wurm M, Dierich MP, Teppner H (1999). Uncaria tomentosa (Willd.) DC. — ethnomedicinal use and new pharmacological, toxicological and botanical results. Journal of Ethnopharmacology 64(1): 23–34. — PubMed PMID: 10075119
6. Wurm M, Kacani L, Laus G, Keplinger K, Dierich MP (1998). Pentacyclic oxindole alkaloids from Uncaria tomentosa induce human endothelial cells to release a lymphocyte-proliferation-regulating factor. Planta Medica 64(8): 701–704. — PubMed PMID: 9933988
7. Sheng Y, Li L, Holmgren K, Pero RW (2001). DNA repair enhancement of aqueous extracts of Uncaria tomentosa in a human volunteer study. Phytomedicine 8(4): 275–282. — PubMed PMID: 11515717
8. Sandoval M, Okuhama NN, Zhang XJ, Condezo LA, Lao J, Angeles' FM, Musah RA, Bobrowski P, Miller MJ (2002). Anti-inflammatory and antioxidant activities of cat's claw (Uncaria tomentosa and Uncaria guianensis) are independent of their alkaloid content. Phytomedicine 9(4): 325–337. — PubMed PMID: 12120814
9. Szilvásy N, Lajer P, Horváth A, Veres K, Hohmann J, Schelz Z, Minorics R, Zupkó I, Gáborik Z, Kis E, Temesszentandrási-Ambrus C (2024). Modulation of multispecific transporters by Uncaria tomentosa extract and its major phytoconstituents. Pharmaceutics 16(11): 1363. — PubMed PMID: 39598486
10. Keyßer G, Sander O, Frohne I, Pfeil A, Michalsen A, Schultz O, Reuß-Borst M, Seifert O; DGRh-Kommission für Komplementäre Heilverfahren und Ernährung (2026). Recommendations of the German Society for Rheumatology committee for complementary treatment and nutrition on phytotherapy: supplement on the use of selected phytotherapeutic agents and herbal preparations in rheumatology: extension to include 13 medicinal plants [article in German]. Zeitschrift für Rheumatologie 85(8): 655–672. — PubMed PMID: 42448806
11. de Paula LC, Fonseca F, Perazzo F, Cruz FM, Cubero D, Trufelli DC, Martins SP, Santi PX, da Silva EA, Del Giglio A (2015). Uncaria tomentosa (cat's claw) improves quality of life in patients with advanced solid tumors. Journal of Alternative and Complementary Medicine 21(1): 22–30. — PubMed PMID: 25495394
12. Del Giglio A (2026). Amazonian and related phytotherapy for cancer-related fatigue: a narrative review of clinical and mechanistic evidence. Integrative Cancer Therapies 25: 15347354261498229. — PubMed PMID: 42878429

Back to Table of Contents

External Authoritative Resources

• U.S. National Center for Complementary and Integrative Health (NCCIH) — Herbs at a Glance (US National Center for Complementary and Integrative Health)
• U.S. National Center for Complementary and Integrative Health — Cat's Claw
• Memorial Sloan Kettering — Cat's Claw monograph (clinical summary with drug-interaction tables)
• WHO Monographs on Selected Medicinal Plants — Volume 3 covers Uncaria tomentosa
• PubMed — all research on Uncaria tomentosa (~1,200+ papers)

Back to Table of Contents

Connections

• All Herbs
• Cat's Claw (Main Page)
• Cat's Claw for Immune Modulation
• Cat's Claw for Rheumatoid Arthritis
• Cat's Claw Anti-Inflammatory (NF-kB)
• Cat's Claw for Lyme Disease (Adjunctive)
• Andrographis
• Astragalus
• Echinacea
• Japanese Knotweed
• Turmeric
• Berberine
• Goldenseal
• Pau d'Arco
• Neem
• Rheumatoid Arthritis
• Lyme Disease
• Crohn's Disease
• Urinary Tract Infections
• Immune Boosting
• History

Back to Table of Contents

Featured Videos

×